share_log

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga Real-time News ·  Jan 31, 2023 05:31

Gainers

  • Nymox Pharmaceutical (NASDAQ:NYMX) shares rose 21.8% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $45.2 million.
  • Brainstorm Cell (NASDAQ:BCLI) stock rose 10.83% to $1.93. The company's market cap stands at $70.6 million.
  • OKYO Pharma (NASDAQ:OKYO) stock moved upwards by 6.46% to $2.8. The company's market cap stands at $60.9 million.
  • Creative Medical Tech (NASDAQ:CELZ) stock rose 6.28% to $0.57. The market value of their outstanding shares is at $8.0 million.
  • Athenex (NASDAQ:ATNX) stock rose 5.44% to $0.19. The company's market cap stands at $29.8 million.
  • Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 5.28% to $0.78. The company's market cap stands at $9.9 million.

Losers

  • Xilio Therapeutics (NASDAQ:XLO) stock fell 9.3% to $3.6 during Monday's after-market session. The market value of their outstanding shares is at $98.8 million.
  • Sonnet BioTherapeutics (NASDAQ:SONN) shares declined by 8.2% to $1.12. The company's market cap stands at $8.8 million.
  • Integer Holdings (NYSE:ITGR) shares fell 7.41% to $65.5. The company's market cap stands at $2.1 billion.
  • Heart Test Laboratories (NASDAQ:HSCS) stock declined by 6.39% to $2.2. At the close, Heart Test Laboratories's trading volume reached 2.6 million shares. This is 6319.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $18.3 million.
  • ASLAN Pharma (NASDAQ:ASLN) shares declined by 5.77% to $0.64. The market value of their outstanding shares is at $44.6 million.
  • Calithera Biosciences (NASDAQ:CALA) stock fell 5.66% to $0.42. The market value of their outstanding shares is at $2.0 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment